新型冠状病毒肺炎恢复期的病理机制及其中医药治疗
The pathological mechanism of the COVID-19 convalescence and its treatment with traditional Chinese medicine.
作者信息
Jiang Linlin, An Xuedong, Duan Yingying, Lian Fengmei, Jin De, Zhang Yuehong, Yang Cunqing, Zhang Yuqing, Kang Xiaomin, Sun Yuting
机构信息
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Beijing University of Chinese Medicine, Beijing, China.
出版信息
Front Pharmacol. 2023 Jan 10;13:1054312. doi: 10.3389/fphar.2022.1054312. eCollection 2022.
The severe acute respiratory syndrome coronavirus - 2 (SARS - CoV - 2) was reported to cause the Wuhan outbreak of the corona virus disease 2019(COVID-19). To date, the COVID-19 has infected more than 600 million people gloabally. As a growing number of patients recover from acute infections and are discharged from hospitals, the proportion of patients in the recovery period is gradually increasing. Many of these individuals have been reported to experience multiple symptoms during the convalescence, such as fatigue, dyspnea and pain which are designated as "long-COVID", "post-COVID syndrome" or "recovery sequelae. We searched for recent articles published in PubMed on COVID-19 convalescence and found that the pathogenesis of COVID-19 convalescence is not yet well recognized. It may be associated with incomplete recovery of immune system, parenchymal organ damage (liver or lung), coagulation abnormalities, "second hit" caused by viral infection, and Phenomenon of Cell Senescence-Associated Secretory Phenotype (SASP). Some drugs and psychological factors of patients also play a non-negligible role in it. We also found that the effect of traditional Chinese medicine (TCM) is effective in the treatment of the COVID-19 recovery phase, which can not only relieve the corresponding symptoms, but also improve the indicators and pulmonary fibrosis. Bufei Huoxue Capsule, as the only drug explicitly mentioned for COVID-19 recovery period, can exert strong rehabilitative effects on physiological activity in patients recovering from COVID-19. In addition, in previous studies, traditional Chinese medicine has been confirmed to have the ability to resist cytokine storms, as well as improve coagulation and myocardial damage, which makes it have potential therapeutic advantages in targeting the hyperimmune response, coagulation abnormalities and myocardial damage existing in the recovery period. In conclusion, the clinical symptoms of patients convalescing from COVID-19 are complex, and its pathogenesis has not been elucidated. traditional Chinese medicine, as a traditional treatment, its specific action and mechanism need to be confirmed by more studies, so that it can play a better role.
据报道,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发了2019年冠状病毒病(COVID-19)的武汉疫情。截至目前,COVID-19已在全球感染了超过6亿人。随着越来越多的患者从急性感染中康复并出院,恢复期患者的比例逐渐增加。据报道,这些患者中有许多人在康复期出现多种症状,如疲劳、呼吸困难和疼痛等,这些症状被称为“长新冠”、“新冠后综合征”或“康复后遗症”。我们检索了PubMed上最近发表的关于COVID-19康复期的文章,发现COVID-19康复期的发病机制尚未得到充分认识。它可能与免疫系统未完全恢复、实质器官损伤(肝脏或肺部)、凝血异常、病毒感染引起的“二次打击”以及细胞衰老相关分泌表型(SASP)现象有关。患者的一些药物和心理因素在其中也起着不可忽视的作用。我们还发现,中药在治疗COVID-19康复期有效,不仅可以缓解相应症状,还可以改善指标和肺纤维化。补肺活血胶囊作为唯一明确提及用于COVID-19康复期的药物,对从COVID-19康复的患者的生理活动具有强大的康复作用。此外,在以往的研究中,中药已被证实具有抵抗细胞因子风暴的能力,以及改善凝血和心肌损伤的能力,这使其在针对康复期存在的高免疫反应、凝血异常和心肌损伤方面具有潜在的治疗优势。总之,COVID-19康复期患者的临床症状复杂,其发病机制尚未阐明。中药作为传统疗法,其具体作用和机制需要更多研究来证实,以便更好地发挥作用。